company news
2018.12.07 size

on dec 7, 2018, hansoh’s ruiyisheng® (prucalopride succinate tablets) (available in 1mg and 2mg) received nda approval from national medical products administration to launch as a category 4 first-to-market generic drug under the new classification system for registration of chemical drugs, equivalent to passing the consistency evaluation.

prucipabride succinate is a highly selective 5-ht4 receptor agonist for the treatment of severe chronic constipation, which can significantly improve patients’ function of intestinal, reduce the severity of symptoms, and only need to be taken once a day.